Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Stopped early · Not applicable

Conditions studied: Atopic Dermatitis

In brief

This study is designed to evaluate and compare the efficacy of 3% oregano extract ointment prepared in aqueous solution versus 1% hydrocortisone ointment, a standard treatment, in decreasing the inflammation associated with mild to moderate atopic dermatitis. We plan to recruit 40 patients on the ages comprised between 2 and 17 years old and the study duration for each of the patient is 1 month.

Key facts

Study ID

NCT02289989

Run by

Rutgers, The State University of New Jersey

People needed

1

Starts

2014-11-01

Expected to finish

2017-01-01

Last updated by the study team

2017-05-10

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or non-pregnant female subjects aged 2-17 years of age.
• Individuals must be diagnosed with acute-subacute AD regardless of the study.
• Written informed consent must be obtained from all patients or caregivers.
• Women of childbearing potential (WOCBP) must be willing to practice effective contraception for the duration of study treatment.
• Subjects must be willing and able to comply with study conditions, properly apply or have caregivers apply topical medications to the selected body sites, as well as return to the clinic for required visits.
• Subject caregivers must be willing and able to perform ADQ assessment test.

You may not qualify if…

• Individuals who are immune-compromised or suffering from infectious disease, malignant disease, are known to be HIV+ or present with a general reduced level of health.
• Individuals diagnosed with underlying dermatological conditions in addition to AD.
• Individuals with a chronic pre-existing disease such as diabetes mellitus or others that in the opinion of the investigator would preclude their participation in the study.
• Individuals who are pregnant, nursing mothers, or subjects planning a pregnancy during the course of the study.
• Subjects/caregivers who are unable to communicate or comply with study conditions due to language disability, poor mental development, or impaired cerebral function.
• Individuals who are simultaneously enrolled in another clinical drug or device research study.
• Individuals with a history of chronic steroid use.
• Individuals needing to concurrently use topical agents, medicinal products containing corticosteroids, or immunosuppressants.
• Individuals who have received systemically administered corticosteroids and/or antihistamines 2 weeks prior to the start of study.
• Individuals undergoing light therapy.
• Individuals who have been treated with another investigation device or drug within 30 days prior to study enrollment.
• Individuals with a known allergy to oregano.

Where it is running

• Department of Dermatology. Rutgers-RWJMS — Somerset, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.